Calithera Biosciences (CALA) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its holdings in Calithera Biosciences (NASDAQ:CALA) by 20.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 132,678 shares of the biotechnology company’s stock after purchasing an additional 22,688 shares during the quarter. Bank of New York Mellon Corp owned about 0.37% of Calithera Biosciences worth $1,108,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN lifted its stake in Calithera Biosciences by 25.8% in the 3rd quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock valued at $531,000 after acquiring an additional 6,910 shares in the last quarter. California Public Employees Retirement System lifted its stake in Calithera Biosciences by 210.1% in the 3rd quarter. California Public Employees Retirement System now owns 43,719 shares of the biotechnology company’s stock valued at $689,000 after acquiring an additional 29,619 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its stake in Calithera Biosciences by 56.2% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 55,580 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 20,000 shares in the last quarter. Alps Advisors Inc. bought a new stake in Calithera Biosciences in the 4th quarter valued at approximately $328,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in Calithera Biosciences by 56.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 112,235 shares of the biotechnology company’s stock valued at $938,000 after acquiring an additional 40,635 shares in the last quarter. Institutional investors and hedge funds own 68.37% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have recently issued reports on CALA shares. Leerink Swann reiterated an “outperform” rating on shares of Calithera Biosciences in a research note on Friday, April 6th. Zacks Investment Research cut Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. Citigroup upgraded Calithera Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $6.95 to $14.00 in a research note on Friday, February 16th. ValuEngine cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 3rd. Finally, BidaskClub cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 18th. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Calithera Biosciences currently has a consensus rating of “Hold” and an average target price of $18.00.



Shares of Calithera Biosciences stock opened at $6.10 on Monday. Calithera Biosciences has a 12-month low of $5.35 and a 12-month high of $20.05. The company has a market cap of $218.65, a PE ratio of -7.26 and a beta of 2.62.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.09). Calithera Biosciences had a negative return on equity of 17.49% and a negative net margin of 107.21%. The company had revenue of $7.24 million for the quarter, compared to the consensus estimate of $7.28 million. During the same quarter in the prior year, the company earned ($0.45) EPS. research analysts forecast that Calithera Biosciences will post -1.21 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/04/23/calithera-biosciences-cala-shares-bought-by-bank-of-new-york-mellon-corp.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply